Development, Evaluation, and Immune Feature Analysis of Prognostic Models for FDX1 and SLC31A1 in Glioma (IMAGE)

Sichuan International Medical Exchange and Promotion Association

Development, Evaluation, and Immune Feature Analysis of Prognostic Models for FDX1 and SLC31A1 in Glioma

Caption

The risk prediction model based on FDX1 and SLC31A1 demonstrated exceptional stratification capability and predictive performance in both the TCGA and CGGA clinical cohorts (Figures A–C). In decision curve analysis (DCA), our model outperformed multiple other risk models in predicting 2-, 3-, and 5-year survival (Figures D–I). Furthermore, a comprehensive analysis of the immune microenvironment revealed that the high-risk group exhibited a more pronounced immunosuppressive phenotype (Figures J–L).

Credit

Minfeng Shu

Usage Restrictions

Please cite the source.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.